Prexa Pharmaceuticals Inc., a Boston biotech focused on developments to treat central nervous system disorders, has appointed Evelyn Graham and Scott Reines as new members of its executive team, the company announced in a news release  today. Graham is taking the chief operating officer post, while Reines is taking the role of chief medical officer. The company filed federal documents on Friday indicating that it had raised $3.25 million  of a planned $7 million equity round.
Graham joins Prexa having previously served as COO and CEO of TorreyPines Therapeutics Inc., a biotech also focused on central nervous system disorder treatments. Her earlier roles included senior management positions at Purdue Pharma; Ingenix Pharmaceutical Services, a division of UHG; Worldwide Clinical Trials Inc.; and Bayer Corp. She earned an MBA degree from the University of Connecticut and a bachelor’s degree in biology from the University of Delaware.